Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973683 · ClinicalTrials.gov registry record · Phase 1
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
A Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04973683: Active Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT04973683 is a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 14 participants, below the 127-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04973683, a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase Ib trial studies the side effects and possible benefits of AL101 before surgery in treating patients with notch activated adenoid cystic cancer. AL101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving AL101 before surgery may help to control adenoid cystic cancer that has a NOTCH pathway activation.
Primary Outcome
Adverse events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Frequency tables will summarize toxicity data for all patients. Logistic regression may be utilized to assess the effect of patient prognostic factors on the response and toxicity.
Conditions Studied
Interventions
- PROCEDURE Therapeutic Conventional Surgery
- DRUG AL101
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 1 |
What the registry record for NCT04973683 still lists
NCT04973683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 127-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Therapeutic Conventional Surgery is the first listed.
NCT04973683 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04973683 about?
NCT04973683 is a clinical study titled "AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer". This phase Ib trial studies the side effects and possible benefits of AL101 before surgery in treating patients with notch activated adenoid cystic cancer. AL101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving AL101 before surgery may help to control...
What is the current status of trial NCT04973683?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-09-30. Estimated completion is 2025-12-15.
What conditions does trial NCT04973683 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT04973683?
The interventions under investigation include: Therapeutic Conventional Surgery (PROCEDURE), AL101 (DRUG).
Who is sponsoring clinical trial NCT04973683?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04973683 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04973683's enrollment target sits among peer trials
14 17th of 16 the lowest of 16 other Adenoid Cystic Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenoid Cystic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
RECRUITING · Phase 1
-
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
RECRUITING · Phase 1
-
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RECRUITING · Phase 1
-
A Study of XMT-1660 in Participants With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy